Literature DB >> 31821129

Assessing factors associated with discharge from opioid agonist therapy due to incarceration in the United States.

Phillip L Marotta1, Kristi L Stringer2,3, Amar D Mandavia4,5, Alissa Davis2,3, Leo Beletsky5,6,7, Tim Hunt1,2, Dawn Goddard-Eckrich1,2, Elwin Wu1,2, Louisa Gilbert1,2, Nabila El-Bassel1,2.   

Abstract

The following study investigates factors associated with discharge from OAT due to incarceration in a sample of 64,331 discharges in the United States. Multinomial regression investigated the association between demographic factors, prior arrest, referral source (i.e criminal justice agency) intravenous drug use, types of drug used, length of prior treatment and discharge due to incarceration compared to completing treatment or discharge due to other reasons. African Americans, Latinx, and Native Americans were at greater risk of discharge due to incarceration compared to whites. Referral to OAT from criminal justice agencies and self-referral was associated with increased risk of discharge from OAT due to incarceration compared to referral from a health care provider. Substance use of heroin, benzodiazepines, synthetic opioids, cocaine and non-prescription use of methadone were associated with discharge due to incarceration. Risk of discharge due to incarceration was higher for patients who reported intravenous drug use and who reported a co-morbid psychiatric problem. These findings enrich a nascent body of literature on mechanisms associated with attrition from OAT due to incarceration and emphasize the need for programs to divert people with OUD from incarceration to increase engagement and retention in OAT.

Entities:  

Keywords:  Opioid Agonist Therapy; attrition; incarceration

Mesh:

Substances:

Year:  2019        PMID: 31821129      PMCID: PMC7224404          DOI: 10.1080/10550887.2019.1690365

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  52 in total

1.  1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.

Authors:  Johan Kakko; Kerstin Dybrandt Svanborg; Mary Jeanne Kreek; Markus Heilig
Journal:  Lancet       Date:  2003-02-22       Impact factor: 79.321

2.  Collateral damage and the criminalisation of drug use.

Authors:  Lisa Maher; Thomas Crewe Dixon
Journal:  Lancet HIV       Date:  2017-05-14       Impact factor: 12.767

3.  Confronting the stigma of opioid use disorder--and its treatment.

Authors:  Yngvild Olsen; Joshua M Sharfstein
Journal:  JAMA       Date:  2014-04-09       Impact factor: 56.272

4.  Differences in successful treatment completion among pregnant and non-pregnant American women.

Authors:  Ethan Sahker; Jennifer E McCabe; Stephan Arndt
Journal:  Arch Womens Ment Health       Date:  2015-04-01       Impact factor: 3.633

5.  Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections.

Authors:  Peter D Friedmann; Donna Wilson; Hannah K Knudsen; Lori J Ducharme; Wayne N Welsh; Linda Frisman; Kevin Knight; Hsiu-Ju Lin; Amy James; Carmen E Albizu-Garcia; Jennifer Pankow; Elizabeth A Hall; Terry F Urbine; Sami Abdel-Salam; Jamieson L Duvall; Frank J Vocci
Journal:  J Subst Abuse Treat       Date:  2014-10-14

Review 6.  A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders.

Authors:  Robert E Drake; Erica L O'Neal; Michael A Wallach
Journal:  J Subst Abuse Treat       Date:  2007-06-15

7.  Criminal justice continuum for opioid users at risk of overdose.

Authors:  Lauren Brinkley-Rubinstein; Nickolas Zaller; Sarah Martino; David H Cloud; Erin McCauley; Andrew Heise; David Seal
Journal:  Addict Behav       Date:  2018-02-24       Impact factor: 3.913

8.  Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes.

Authors:  Harlan Matusow; Samuel L Dickman; Josiah D Rich; Chunki Fong; Dora M Dumont; Carolyn Hardin; Douglas Marlowe; Andrew Rosenblum
Journal:  J Subst Abuse Treat       Date:  2012-12-03

9.  Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.

Authors:  Yih-Ing Hser; Andrew J Saxon; David Huang; Al Hasson; Christie Thomas; Maureen Hillhouse; Petra Jacobs; Cheryl Teruya; Paul McLaughlin; Katharina Wiest; Allan Cohen; Walter Ling
Journal:  Addiction       Date:  2013-10-09       Impact factor: 6.526

10.  Racial and Ethnic Disparities in Outpatient Substance Use Disorder Treatment Episode Completion for Different Substances.

Authors:  Jeremy Mennis; Gerald J Stahler
Journal:  J Subst Abuse Treat       Date:  2015-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.